Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.82 |
| ▸ | PGR | P06401 | 3/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | AR | P10275 | 2/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | APEX1 | P27695 | 1/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | IKBKB | O14920 | 1/20 | 0.82 |
| ▸ | CHUK | O15111 | 1/20 | 0.82 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.82 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.82 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.82 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898449 | 0.95 | NR3C1 (0.76) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| SCHEMBL73249 | 0.95 | NR3C1 (0.76) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| SCHEMBL15671680 | 0.95 | NR3C1 (0.76) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| SCHEMBL3126388 | 0.95 | NR3C1 (0.75) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| SCHEMBL1301198 | 0.95 | NR3C1 (0.75) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Water SCHEMBL201856 | 0.95 | NR3C1 (0.75) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| SCHEMBL2123848 | 0.95 | NR3C1 (0.75) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| SCHEMBL3836633 | 0.95 | NR3C1 (0.75) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| SCHEMBL5912759 | 0.95 | NR3C1 (0.75) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL5501682 | 0.92 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165130-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-23 | — | — | US | disclosed |
| CN-115348963-B | Pyridopyrimidine compound and application thereof | 暨南大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-113966331-B | Triaryl ring compound containing urea structure and application thereof | 暨南大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-114072387-B | Indazole compound, pharmaceutical composition and application thereof | 暨南大学 | 2024-03-08 | — | — | CN | disclosed |
| CN-117642408-A | Selenium-containing heterocyclic compound, and pharmaceutical composition and application thereof | 暨南大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-116848094-A | Tertiary amine lipid compounds and uses thereof | 华南理工大学 | 2023-10-03 | — | — | CN | disclosed |
| CN-114761410-B | Pyrrolopyrimidinone compounds and application thereof | 广州必贝特医药股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116635080-A | PH-sensitive membrane-rupture polypeptide and application thereof | 华南理工大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-113166110-B | 2-aminopyrimidine compound and application thereof | 暨南大学 | 2023-08-11 | — | — | CN | disclosed |
| CN-116462616-A | Alkynylamide compounds and application thereof | 暨南大学 | 2023-07-21 | — | — | CN | disclosed |
| US-20160263024-A1 | DELIVERY OF CORTICOSTEROIDS THROUGH IONTOPHORESIS | EYEGATE PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9149525-B2 | Delivery of corticosteroids through iontophoresis | EYEGATE PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140046242-A1 | DELIVERY OF CORTICOSTEROIDS THROUGH IONTOPHORESIS | EYEGATE PHARMACEUTICALS, INC. | 2014-02-13 | — | — | US | disclosed |
| US-20120283231-A1 | Delivery Of Corticosteroids Through Iontophoresis | EYEGATE PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| CN-101970042-A | Enhanced delivery of therapeutic agents to ocular tissues via iontophoresis | EYEGATE PHARMA S A S | 2011-02-09 | — | — | CN | disclosed |
| EP-2249921-A2 | ENHANCED DELIVERY OF A THERAPEUTIC TO OCULAR TISSUES THROUGH IONTOPHORESIS | Eyegate Pharma S.A.S. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20090306579-A1 | DELIVERY OF CORTICOSTEROIDS THROUGH IONTOPHORESIS | EYEGATE PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| WO-2009108626-A2 | ENHANCED DELIVERY OF A THERAPEUTIC TO OCULAR TISSUES THROUGH IONTOPHORESIS | EYEGATE PHARMA S.A.S. (US) | 2009-09-03 | — | — | WO | disclosed |
| EP-1973519-A1 | FORMULATIONS OF LOW OIL CONTENT COMPRISING DIPHENYLMETHANE DERIVATIVES | Symrise GmbH & Co. KG (DE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007077260-A1 | FORMULATIONS OF LOW OIL CONTENT COMPRISING DIPHENYLMETHANE DERIVATIVES | SYMRISE GMBH & CO. KG (DE) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165130-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | LIPC, LIPA, FABP4 | NR3C1 108/4885HIF1A 4001/4885CYP3A4 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.